<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">17191303</PMID>
      <DateCompleted>
        <Year>2007</Year>
        <Month>03</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0513-5796</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>47</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2006</Year>
              <Month>Dec</Month>
              <Day>31</Day>
            </PubDate>
          </JournalIssue>
          <Title>Yonsei medical journal</Title>
          <ISOAbbreviation>Yonsei Med J</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Kawasaki disease.</ArticleTitle>
        <Pagination>
          <StartPage>759</StartPage>
          <EndPage>772</EndPage>
          <MedlinePgn>759-72</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Kawasaki disease is an acute febrile, systemic vasculitic syndrome of an unknown etiology that primarily occurs in children younger than five years of age. The principal presentations of Kawasaki disease include fever, bilateral nonexudative conjunctivitis, erythema of the lips and oral mucosa, changes in the extremities, rash, and cervical lymphadenopathy. Coronary artery aneurysms or ectasia develops in 15% to 25% of untreated children with the disease, which may later lead to myocardial infarction, sudden death, or ischemic heart disease. Treatment with intravenous gamma globulin (IVIG) is effective, but the mode of action is still unclear. The development of a diagnostic test, a more specific therapy, and ultimately the prevention of this potentially fatal illness in children are all dependent upon the continued advances in determining the etiopathogenesis of this fascinating disorder.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Dong Soo</ForeName>
            <Initials>DS</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Infectious Disease and Immunology, Department of Pediatrics, Yonsei University College of Medicine, Severance Children's Hospital, Seoul, Korea. dskim6634@yumc.yonsei.ac.kr</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Yonsei Med J</MedlineTA>
        <NlmUniqueID>0414003</NlmUniqueID>
        <ISSNLinking>0513-5796</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>R16CO5Y76E</RegistryNumber>
          <NameOfSubstance UI="D001241">Aspirin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001241" MajorTopicYN="N">Aspirin</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009080" MajorTopicYN="N">Mucocutaneous Lymph Node Syndrome</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2006</Year>
          <Month>12</Month>
          <Day>28</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2007</Year>
          <Month>3</Month>
          <Day>6</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2006</Year>
          <Month>12</Month>
          <Day>28</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">17191303</ArticleId>
        <ArticleId IdType="pmc">PMC2687814</ArticleId>
        <ArticleId IdType="doi">10.3349/ymj.2006.47.6.759</ArticleId>
        <ArticleId IdType="pii">200612759</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children [in Japanese] Arerugi. 1967;16:178–222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6062087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamoto T, Oya T, Watanabe A, et al.  Clinical features of Kawasaki disease [in Japanese] Shonika Rinsho (Jpn J Pediatr) 1968;21:291–297.</Citation>
        </Reference>
        <Reference>
          <Citation>Kosaki F, Kawasaki T, Okawa S, et al.  Clinicopathological conference on 10 fatal cases with acute febrile mucocutaneous lymph node syndrome [in Japanese] Shonika Rinsho (Jpn J Pediatr) 1971;24:2545–2559.</Citation>
        </Reference>
        <Reference>
          <Citation>Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974;54:271–276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4153258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burns JC, Wiggins JW, Jr, Toews WH, Newburger JW, Leung DY, Wilson H, et al.  Clinical spectrum of Kawasaki disease in infants younger than 6 months of age. J Pediatr. 1986;109:759–763.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3772656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suddleson EA, Reid B, Woolley MM, Takahashi M. Hydrops of the gallbladder associated with Kawasaki syndrome. J Pediatr Surg. 1987;22:956–959.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3316594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roh TW, Park MC, Kim DS. Antibody response against 65kD heat shock protein in Kawasaki disease [in Korean] Pediatr Allergy Respir Dis. 1993;3:68–72.</Citation>
        </Reference>
        <Reference>
          <Citation>Kim HY, Kim DS, Shin JS. NRAMP1 Gene Expression in Patients with Kawasaki Disease [in Korean] Pediatr Allergy Respir Dis. 2000;10:153–160.</Citation>
        </Reference>
        <Reference>
          <Citation>Kim HS, Noh GW, Kim DS, Lee KY, Lee HS, Lee HK, et al.  Decreased CD5+ B cells during the acute phase of Kawasaki disease. Yonsei Med J. 1996;37:52–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8967110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim HY, Lee HG, Kim DS. Apoptosis of peripheral blood mononuclear cells in Kawasaki disease. J Rheumatol. 2000;27:801–806.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10743828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dengler LD, Capparelli EV, Bastian JF, Bradley DJ, Glode MP, Santa S, et al.  Cerebrospinal fluid profile in patients with acute Kawasaki disease. Pediatr Infect Dis J. 1998;17:478–481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9655538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okada T, Harada K, Okuni M. Serum HDL-cholesterol and lipoprotein fraction in Kawasaki disease (acute mucocutaneous lymph node syndrome) Jpn Circ J. 1982;46:1039–1044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6956753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newburger JW, Burns JC, Beiser AS, Loscalzo J. Altered lipid profile after Kawasaki syndrome. Circulation. 1991;84:625–631.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1860206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cabana VG, Gidding SS, Getz GS, Chapman J, Shulman ST. Serum amyloid A and high density lipoprotein participate in the acute phase response of Kawasaki disease. Pediatr Res. 1997;42:651–655.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9357939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenfeld EA, Corydon KE, Shulman ST. Kawasaki disease in infants less than one year of age. J Pediatr. 1995;126:524–529.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7699529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Momenah T, Sanatani S, Potts J, Sandor GG, Human DG, Patterson MW. Kawasaki disease in the older child. Pediatrics. 1998;102:e7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9651459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stockheim JA, Innocentini N, Shulman ST. Kawasaki disease in older children and adolescents. J Pediatr. 2000;137:250–252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10931420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yanagawa H, Nakamura Y, Yashiro M, Oki I, Hirata S, Zhang T, et al.  Incidence survey of Kawasaki disease in 1997 and 1998 in Japan. Pediatrics. 2001;107:E33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11230614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holman RC, Curns AT, Belay ED, Steiner CA, Schonberger LB. Kawasaki syndrome hospitalizations in the United States, 1997 and 2000. Pediatrics. 2003;112:495–501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12949272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang RK. The incidence of Kawasaki disease in the United States did not increase between 1988 and 1997. Pediatrics. 2003;111:1124–1125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12728105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park YW, Han JW, Park IS, Kim CH, Yun YS, Cha SH, et al.  Epidemiologic picture of Kawasaki disease in Korea, 2000-2002. Pediatr Int. 2005;47:382–387.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16091073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yanagawa H, Nakamura Y, Yashiro M, Ojima T, Tanihara S, Oki I, et al.  Results of the nationwide epidemiologic survey of Kawasaki disease in 1995 and 1996 in Japan. Pediatrics. 1998;102:E65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9832593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujita Y, Nakamura Y, Sakata K, Hara N, Kobayashi M, Nagai M, et al.  Kawasaki disease in families. Pediatrics. 1989;84:666–669.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2780128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harada F, Sada M, Kamiya T, Yanase Y, Kawasaki T, Sasazuki T. Genetic analysis of Kawasaki syndrome. Am J Hum Genet. 1986;39:537–539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1683975</ArticleId>
            <ArticleId IdType="pubmed">3766546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yanagawa H, Yashiro M, Nakamura Y, Kawasaki T, Kato H. Epidemiologic pictures of Kawasaki disease in Japan: from the nationwide incidence survey in 1991 and 1992. Pediatrics. 1995;95:475–479.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7700743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaneko K, Obinata K, Katsumata K, Tawa T, Hosaka A, Yamashiro Y. Kawasaki disease in a father and daughter. Acta Paediatr. 1999;88:791–792.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10447146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bruckheimer E, Bulbul Z, McCarthy P, Madri JA, Friedman AH, Hellenbrand WE. Images in cardiovascular medicine. Kawasaki disease: coronary aneurysms in mother and son. Circulation. 1998;97:410–411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9468215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uehara R, Yashiro M, Nakamura Y, Yanagawa H. Kawasaki disease in parents and children. Acta Paediatr. 2003;92:694–697.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12856980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abe J, Kotzin BL, Jujo K, Melish ME, Glode MP, Kohsaka T, et al.  Selective expansion of T cells expressing T-cell receptor variable regions V beta 2 and V beta 8 in Kawasaki disease. Proc Natl Acad Sci USA. 1992;89:4066–4070.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC525633</ArticleId>
            <ArticleId IdType="pubmed">1315049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim DS, Han BH, Lee SK, Lee HK, Chwae YJ, Lee KY. Evidence for selection of 11 amino acid CDR3 domains in V kappa III-derived immunoglobulin light chains in Kawasaki disease. Scand J Rheumatol. 1997;26:350–354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9385345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leung DY, Giorno RC, Kazemi LV, Flynn PA, Busse JB. Evidence for superantigen involvement in cardiovascular injury due to Kawasaki syndrome. J Immunol. 1995;155:5018–5021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7594509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leung DY, Meissner HC, Shulman ST, Mason WH, Gerber MA, Glode MP, et al.  Prevalence of super-antigen-secreting bacteria in patients with Kawasaki disease. J Pediatr. 2002;140:742–746.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12072880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi IH, Chwae YJ, Shim WS, Kim DS, Kwon DH, Kim JD, et al.  Clonal expansion of CD8+ T cells in Kawasaki disease. J Immunol. 1997;159:481–486.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9200489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rowley AH, Shulman ST, Spike BT, Mask CA, Baker SC. Oligoclonal IgA response in the vascular wall in acute Kawasaki disease. J Immunol. 2001;166:1334–1343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11145718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee JS, Park IH, Shin JS, Kim DS. Clonal Expansion of Peripheral B Cells in Kawasaki Disease [in Korean] Pediatr Allergy Respir Dis. 2002;12:299–314.</Citation>
        </Reference>
        <Reference>
          <Citation>Shulman ST, Melish M, Inoue O, Kato H, Tomita S. Immunoglobulin allotypic markers in Kawasaki disease. J Pediatr. 1993;122:84–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8419619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeuchi K, Yamamoto K, Kataoka S, Kakihara T, Tanaka A, Sato S, et al.  High incidence of angiotensin I converting enzyme genotype II in Kawasaki disease patients with coronary aneurysm. Eur J Pediatr. 1997;156:266–268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9128808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahn SY, Jang GC, Shin JS, Shin KM, Kim DS. Tumor necrosis factor-alpha levels and promoter polymorphism in patients with Kawasaki disease in Korea. Yonsei Med J. 2003;44:1021–1026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14703611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang Y, Lee YJ, Chen MR, Hsu CH, Lin SP, Sung TC, et al.  Polymorphism of transmembrane region of MICA gene and Kawasaki disease. Exp Clin Immunogenet. 2000;17:130–137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10899738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsukahara H, Hiraoka M, Saito M, Nishida K, Kobata R, Tsuchida S, et al.  Methylenetetrahydrofolate reductase polymorphism in Kawasaki disease. Pediatr Int. 2000;42:236–240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10881578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jibiki T, Terai M, Shima M, Ogawa A, Hamada H, Kanazawa M, et al.  Monocyte chemoattractant protein 1 gene regulatory region polymorphism and serum levels of monocyte chemoattractant protein 1 in Japanese patients with Kawasaki disease. Arthritis Rheum. 2001;44:2211–2212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11592387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sohn MH, Hur MW, Kim DS. Interleukin 6 gene promoter polymorphism is not associated with Kawasaki disease. Genes Immun. 2001;2:357–362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11704800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quasney MW, Bronstein DE, Cantor RM, Zhang Q, Stroupe C, Shike H, et al.  Increased frequency of alleles associated with elevated tumor necrosis factor-alpha levels in children with Kawasaki disease. Pediatr Res. 2001;49:686–690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11328953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ouchi K, Suzuki Y, Shirakawa T, Kishi F. Polymorphism of SLC11A1 (formerly NRAMP1) gene confers susceptibility to Kawasaki disease. J Infect Dis. 2003;187:326–329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12552460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishimura S, Zaitsu M, Hara M, Yokota G, Watanabe M, Ueda Y, et al.  A polymorphism in the promoter of the CD14 gene (CD14/-159) is associated with the development of coronary artery lesions in patients with Kawasaki disease. J Pediatr. 2003;143:357–362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14517520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biezeveld MH, Kuipers IM, Geissler J, Lam J, Ottenkamp JJ, Hack CE, et al.  Association of mannose-binding lectin genotype with cardiovascular abnormalities in Kawasaki disease. Lancet. 2003;361:1268–1270.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12699957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naoe S, Takahashi K, Masuda H, Tanaka N. Kawasaki disease. With particular emphasis on arterial lesions. Acta Pathol Jpn. 1991;41:785–797.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1785339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown TJ, Crawford SE, Cornwall ML, Garcia F, Shulman ST, Rowley AH. CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease. J Infect Dis. 2001;184:940–943.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11528596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gavin PJ, Crawford SE, Shulman ST, Garcia FL, Rowley AH. Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease. Arterioscler Thromb Vasc Biol. 2003;23:576–581.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12692003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furukawa S, Matsubara T, Jujoh K, Yone K, Sugawara T, Sasai K, et al.  Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki disease. Clin Immunol Immunopathol. 1988;48:247–251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3390972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maury CP, Salo E, Pelkonen P. Circulating interleukin-1 beta in patients with Kawasaki disease. N Engl J Med. 1988;319:1670–1671.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3264383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim DS. Serum interleukin-6 in Kawasaki disease. Yonsei Med J. 1992;33:183–188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1413896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jang GC, Kim HY, Ahn SY, Kim DS. Raised serum interleukin 15 levels in Kawasaki disease. Ann Rheum Dis. 2003;62:264–266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1754472</ArticleId>
            <ArticleId IdType="pubmed">12594117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sohn MH, Noh SY, Chang W, Shin KM, Kim DS. Circulating interleukin 17 is increased in the acute stage of Kawasaki disease. Scand J Rheumatol. 2003;32:364–366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15080268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jang GC, Lee SY, Kim DS. Changes of Serum Interleukin-18 Levels in Kawasaki Disease [in Korean] Pediatr Allergy Respir Dis. 2001;11:130–137.</Citation>
        </Reference>
        <Reference>
          <Citation>Kim DS, Lee KY. Serum soluble E-selectin levels in Kawasaki disease. Scand J Rheumatol. 1994;23:283–286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7526448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rowley AH, Shulman ST, Mask CA, Finn LS, Terai M, Baker SC, et al.  IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease. J Infect Dis. 2000;182:1183–1191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10979916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeshita S, Tokutomi T, Kawase H, Nakatani K, Tsujimoto H, Kawamura Y, et al.  Elevated serum levels of matrix metalloproteinase-9 (MMP-9) in Kawasaki disease. Clin Exp Immunol. 2001;125:340–344.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1906124</ArticleId>
            <ArticleId IdType="pubmed">11529928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang CL, Wu YT, Liu CA, Lin MW, Lee CJ, Huang LT, et al.  Expression of CD40 ligand on CD4+ T-cells and platelets correlated to the coronary artery lesion and disease progress in Kawasaki disease. Pediatrics. 2003;111:E140–E147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12563087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maeno N, Takei S, Masuda K, Akaike H, Matsuo K, Kitajima I, et al.  Increased serum levels of vascular endothelial growth factor in Kawasaki disease. Pediatr Res. 1998;44:596–599.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9773852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong M, Silverman ED, Fish EN. Evidence for RANTES, monocyte chemotactic protein-1, and macrophage inflammatory protein-1 beta expression in Kawasaki disease. J Rheumatol. 1997;24:1179–1185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9195529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol. 1990;56:29–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2113446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin CY, Lin CC, Hwang B, Chiang B. Serial changes of serum interleukin-6, interleukin-8, and tumor necrosis factor alpha among patients with Kawasaki disease. J Pediatr. 1992;121:924–926.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1447658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim DS, Lee HK, Noh GW, Lee SI, Lee KY. Increased serum interleukin-10 level in Kawasaki disease. Yonsei Med J. 1996;37:125–130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8711935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim KC, Kim DS. The soluble interleukin 2 receptor levels in Kawasaki disease [in Korean] J Korean Pediatr Soc. 1992;35:1657–1666.</Citation>
        </Reference>
        <Reference>
          <Citation>Hwang DH, Han JW, Choi KM, Shin KM, Kim DS. Expression of Toll-like Receptor-2 on the Peripheral Blood Monocytes in Kawasaki Disease Patients [in Korean] J Korean Pediatr Soc. 2005;48:315–320.</Citation>
        </Reference>
        <Reference>
          <Citation>Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics. 1995;96:1057–1061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7491221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, et al.  High-dose intravenous gammaglobulin for Kawasaki disease. Lancet. 1984;2:1055–1058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6209513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, et al.  The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315:341–347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2426590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morikawa Y, Ohashi Y, Harada K, Asai T, Okawa S, Nagashima M, et al.  A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatr Jpn. 1994;36:347–354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7524263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr. 1997;131:888–893.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9427895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee HK, Kim DS, Noh GW, Lee KY. Effects of intravenous immune globulin on the peripheral lymphocyte phenotypes in Kawasaki disease. Yonsei Med J. 1996;37:357–363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8997168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu C, Poirier B, Van Huyen JP, Lucchiari N, Michel O, Chevalier J, et al.  Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: a possible mechanism of action in vascular diseases. Am J Pathol. 1998;153:1257–1266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1853054</ArticleId>
            <ArticleId IdType="pubmed">9777957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sawaji Y, Haneda N, Yamaguchi S, Kajino Y, Kishida K, Seto S, et al.  Coronary risk factors in acute Kawasaki disease: correlation of serum immunoglobulin levels with coronary complications. Acta Paediatr Jpn. 1998;40:218–225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9695293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang T, Yanagawa H, Oki I, Nakamura Y. Factors relating to the cardiac sequelae of Kawasaki disease one month after initial onset. Acta Paediatr. 2002;91:517–520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12113319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muta H, Ishii M, Egami K, Furui J, Sugahara Y, Akagi T, et al.  Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan. J Pediatr. 2004;144:496–499.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15069399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marasini M, Pongiglione G, Gazzolo D, Campelli A, Ribaldone D, Caponnetto S. Late intravenous gamma globulin treatment in infants and children with Kawasaki disease and coronary artery abnormalities. Am J Cardiol. 1991;68:796–797.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1716411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pickering LK.  Red Book. Chicago (IL): American Academy of Pediatrics; 2003. 2003 Report of the Committee on Infectious Diseases.</Citation>
        </Reference>
        <Reference>
          <Citation>Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics. 1979;63:175–179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">440805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shinohara M, Sone K, Tomomasa T, Morikawa A. Corticosteroids in the treatment of the acute phase of Kawasaki disease. J Pediatr. 1999;135:465–469.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10518080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sundel RP, Baker AL, Fulton DR, Newburger JW. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr. 2003;142:611–616.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12838187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okada Y, Shinohara M, Kobayashi T, Inoue Y, Tomomasa T, Kobayashi T, et al.  Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children. J Pediatr. 2003;143:363–367.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14517521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP US/Canadian Kawasaki Syndrome Study Group. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. Pediatr Infect Dis J. 1998;17:1144–1148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9877364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics. 2000;105:E78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10835091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newburger JW. Kawasaki disease: who is at risk? J Pediatr. 2000;137:149–152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10931403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wright DA, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr. 1996;128:146–149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8551407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takagi N, Kihara M, Yamaguchi S, Tamura K, Yabana M, Tokita Y, et al.  Plasma exchange in Kawasaki disease. Lancet. 1995;346:1307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7475760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zaitsu M, Hamasaki Y, Tashiro K, Matsuo M, Ichimaru T, Fujita I, et al.  Ulinastatin, an elastase inhibitor, inhibits the increased mRNA expression of prostaglandin H2 synthase-type 2 in Kawasaki disease. J Infect Dis. 2000;181:1101–1109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10720537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol. 2004;31:808–810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15088313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuijpers TW, Biezeveld M, Achterhuis A, Kuipers I, Lam J, Hack CE, et al.  Longstanding obliterative panarteritis in Kawasaki disease: lack of cyclosporin A effect. Pediatrics. 2003;112:986–992.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14523200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahn SY, Kim DS. Treatment of intravenous immunoglobulin-resistant Kawasaki disease with methotrexate. Scand J Rheumatol. 2005;34:136–139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16095010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee MS, An SY, Jang GC, Kim DS. A case of intravenous immunoglobulin-resistant Kawasaki disease treated with methotrexate. Yonsei Med J. 2002;43:527–532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12205742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O'Brien M, Parness IA, Neufeld EJ, Baker AL, Sundel RP, Newburger JW. Ticlopidine plus aspirin for coronary thrombosis in Kawasaki disease. Pediatrics. 2000;105:E64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10799628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams RV, Wilke VM, Tani LY, Minich LL. Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease? Pediatrics. 2002;109:E4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11773572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki A, Kamiya T, Kuwahara N, Ono Y, Kohata T, Takahashi O, et al.  Coronary arterial lesions of Kawasaki disease: cardiac catheterization findings of 1100 cases. Pediatr Cardiol. 1986;7:3–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3774580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dajani AS, Taubert KA, Takahashi M, Bierman FZ, Freed MD, Ferrieri P, et al.  Guidelines for long-term management of patients with Kawasaki disease. Report from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 1994;89:916–922.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8313588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akagi T, Kato H, Inoue O, Sato N, Imamura K. Valvular heart disease in Kawasaki syndrome: incidence and natural history. Am Heart J. 1990;120:366–372.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2382613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshikawa J, Yanagihara K, Owaki T, Kato H, Takagi Y, Okumachi F, et al.  Cross-sectional echocardiographic diagnosis of coronary artery aneurysms in patients with the mucocutaneous lymph node syndrome. Circulation. 1979;59:133–139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">758104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Capannari TE, Daniels SR, Meyer RA, Schwartz DC, Kaplan S. Sensitivity, specificity and predictive value of two-dimensional echocardiography in detecting coronary artery aneurysms in patients with Kawasaki disease. J Am Coll Cardiol. 1986;7:355–360.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3944354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, et al.  Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation. 1996;94:1379–1385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8822996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. J Pediatr. 2000;137:177–180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10931408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asai T. Diagnosis and prognosis of coronary artery lesions in Kawasaki disease. Coronary angiography and the conditions for its application (a score chart) [Japanese] Nippon Rinsho. 1983;41:2080–2085.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6663743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koren G, Lavi S, Rose V, Rowe R. Kawasaki disease: review of risk factors for coronary aneurysms. J Pediatr. 1986;108:388–392.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3950818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harada K. Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn. 1991;33:805–810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1801561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beiser AS, Takahashi M, Baker AL, Sundel RP, Newburger JW US Multicenter Kawasaki Disease Study Group. A predictive instrument for coronary artery aneurysms in Kawasaki disease. Am J Cardiol. 1998;81:1116–1120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9605052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hwang DH, Sin KM, Choi KM, Choi JY, Sul JH, Kim DS. Statistical analysis of 1,000 cases of Kawasaki disease patients diagnosed at a single institute. Korean J Pediatr. 2005;48:416–424.</Citation>
        </Reference>
        <Reference>
          <Citation>Takahashi M, Mason W, Lewis AB. Regression of coronary aneurysms in patients with Kawasaki syndrome. Circulation. 1987;75:387–394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3802442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujiwara T, Fujiwara H, Hamashima Y. Size of coronary aneurysm as a determinant factor of the prognosis in Kawasaki disease: clinicopathologic study of coronary aneurysms. Prog Clin Biol Res. 1987;250:519–520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3423060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakano H, Ueda K, Saito A, Nojima K. Repeated quantitative angiograms in coronary arterial aneurysm in Kawasaki disease. Am J Cardiol. 1985;56:846–851.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4061324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishii M, Ueno T, Akagi T, Baba K, Harada K, Hamaoka K, et al.  Guidelines for catheter intervention in coronary artery lesion in Kawasaki disease. Pediatr Int. 2001;43:558–562.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11737728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akagi T, Ogawa S, Ino T, Iwasa M, Echigo S, Kishida K, et al.  Catheter interventional treatment in Kawasaki disease: a report from the Japanese Pediatric Interventional Cardiology Investigation group. J Pediatr. 2000;137:181–186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10931409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kitamura S. The role of coronary bypass operation on children with Kawasaki disease. Coron Artery Dis. 2002;13:437–447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12544719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Checchia PA, Pahl E, Shaddy RE, Shulman ST. Cardiac transplantation for Kawasaki disease. Pediatrics. 1997;100:695–699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9310527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamiya T, Suzuki A, Ono Y. Angiographic follow-up study of coronary artery lesion in the cases with a history of Kawasaki disease-with a focus on the follow-up more than ten years after the onset of the disease. In: Kato H, editor. Kawasaki Disease; Proceedings of the 5th International Kawasaki Disease Symposium; May 22-25, 1995; Fukuoka, Japan. New York (NY): Elsevier Science; 1995. pp. 569–573.</Citation>
        </Reference>
        <Reference>
          <Citation>Fujiwara T, Fujiwara H, Hamashima Y. Frequency and size of coronary arterial aneurysm at necropsy in Kawasaki disease. Am J Cardiol. 1987;59:808–811.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3825941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakano H, Saito A, Ueda K, Nojima K. Clinical characteristics of myocardial infarction following Kawasaki disease: report of 11 cases. J Pediatr. 1986;108:198–203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3944703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tatara K, Kusakawa S. Long-term prognosis of giant coronary aneurysm in Kawasaki disease: an angiographic study. J Pediatr. 1987;111:705–710.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3668739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kato H, Ichinose E, Kawasaki T. Myocardial infarction in Kawasaki disease: clinical analyses in 195 cases. J Pediatr. 1986;108:923–927.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3712157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furukawa S, Matsubara T, Umezawa Y, Okumura K, Yabuta K. Serum levels of p60 soluble tumor necrosis factor receptor during acute Kawasaki disease. J Pediatr. 1994;124:721–725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8176558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsubara T, Umezawa Y, Tsuru S, Motohashi T, Yabuta K, Furukawa S. Decrease in the concentrations of transforming growth factor-beta 1 in the sera of patients with Kawasaki disease. Scand J Rheumatol. 1997;26:314–317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9310113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee TJ, Chun JK, Yeon SI, Shin JS, Kim DS. Increased serum levels of macrophage migration inhibitory factor in patients with Kawasaki disease. Scand J Rheumatol. 2006 In press.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17657678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leung DY, Collins T, Lapierre LA, Geha RS, Pober JS. Immunoglobulin M antibodies present in the acute phase of Kawasaki syndrome lyse cultured vascular endothelial cells stimulated by gamma interferon. J Clin Invest. 1986;77:1428–1435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC424542</ArticleId>
            <ArticleId IdType="pubmed">3084559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mason WH, Jordan SC, Sakai R, Takahashi M, Bernstein B. Circulating immune complexes in Kawasaki syndrome. Pediatr Infect Dis. 1985;4:48–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3881741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Culora GA, Moore IE. Kawasaki disease, Epstein-Barr virus and coronary artery aneurysms. J Clin Pathol. 1997;50:161–163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC499744</ArticleId>
            <ArticleId IdType="pubmed">9155700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burns JC, Glode MP, Clarke SH, Wiggins J, Jr, Hathaway WE. Coagulopathy and platelet activation in Kawasaki syndrome: identification of patients at high risk for development of coronary artery aneurysms. J Pediatr. 1984;105:206–211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6235335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nash MC, Shah V, Reader JA, Dillon MJ. Anti-neutrophil cytoplasmic antibodies and anti-endothelial cell antibodies are not increased in Kawasaki disease. Br J Rheumatol. 1995;34:882–887.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7582731</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
